for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cancer Genetics Inc

CGIX.OQ

Latest Trade

3.22USD

Change

0.01(+0.31%)

Volume

7,796

Today's Range

3.01

 - 

3.24

52 Week Range

1.97

 - 

9.37

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cancer Genetics Posts Q4 Loss Per Share Of $0.14

June 1 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.14.Q4 REVENUE ROSE 12 PERCENT TO $1.9 MILLION.CANCER GENETICS - CONTINUING TO EVALUATE POTENTIAL STRATEGIC OPTIONS INCLUDING COLLABORATIONS, MERGERS/ACQUISITIONS, OR OTHER STRATEGIC TRANSACTIONS.CANCER GENETICS - FILED ANNUAL REPORT ON FORM 10-K FOR YEAR ENDED DEC 31, 2019 ON MAY 29TH WITH SECURITIES AND EXCHANGE COMMISSION.CANCER GENETICS - 2019 AUDITED FINANCIAL STATEMENTS CONTAIN EXPLANATORY PARAGRAPH REGARDING CO'S ABILITY TO CONTINUE AS GOING CONCERN.CANCER GENETICS - DISCLOSED IN FORM 10-K IT HAD CONCLUDED INTERNAL CONTROLS OVER FINANCIAL REPORTING WAS INEFFECTIVE FOR YEAR ENDED DEC 31, 2019.CANCER GENETICS - CONCLUSION OF INTERNAL CONTROLS OVER FINANCIAL REPORTING IN FORM 10-K RESULTED IN CO REPORTING DEFICIENCIES CONSIDERED MATERIAL WEAKNESSES.

Cancer Genetics Q3 Earnings Per Share $0.98

Nov 20 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q3 EARNINGS PER SHARE $0.98.CANCER GENETICS - TOTAL DISCOVERY SERVICES REVENUE OF $2.1 MILLION FOR Q3 OF 2019 COMPARED TO REVENUE OF $0.5 MILLION IN Q3 OF 2018.CANCER GENETICS - RETAINED HC WAINWRIGHT & CO. TO EXPLORE STRATEGIC ALTERNATIVES FOR FUTURE MERGER, SALE OF ASSETS, OR OTHER STRATEGIC TRANSACTIONS.

Cancer Genetics Announces 1-For-30 Reverse Stock Split

Oct 24 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS ANNOUNCES 1-FOR-30 REVERSE STOCK SPLIT.CANCER GENETICS INC - REVERSE STOCK SPLIT WILL BE EFFECTIVE FOR TRADING PURPOSES ON OCTOBER 25, 2019.

Cancer Genetics Posts Q2 Loss Per Share Of $0.01

Aug 20 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q2 LOSS PER SHARE $0.01.QUARTERLY REVENUE$1.5 MILLION VERSUS $1.3 MILLION.CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2019 TOTALED $0.7 MILLION, COMPARED TO $0.2 MILLION AS OF DECEMBER 31, 2018..

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15 (Reuters) - Interpace Diagnostics Group Inc <IDXG.O>::INTERPACE DIAGNOSTICS ACQUIRES CANCER GENETICS’ BIOPHARMA SERVICES BUSINESS SUPPORTED BY INVESTMENT FROM AMPERSAND CAPITAL PARTNERS.INTERPACE DIAGNOSTICS GROUP INC - DEAL FOR $23.5 MILLION.INTERPACE DIAGNOSTICS - PRIVATE EQUITY FIRM IN DIAGNOSTIC/BIOPHARMA SECTOR, TO INVEST $27 MILLION IN TWO TRANCHES OF NEWLY ISSUED CONVERTIBLE PREFERRED STOCK.INTERPACE DIAGNOSTICS - UNDER TERMS, MADE ADDITIONAL PAYMENT OF ABOUT $4.5 MILLION TO CANCER GENETICS.

Cancer Genetics Reports Q1 Loss Per Share Of $0.90

May 20 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q1 LOSS PER SHARE $0.90.Q1 REVENUE FELL 10.8 PERCENT TO $6.8 MILLION.CONTINUE TO WORK WITH RAYMOND JAMES ON A STRATEGIC TRANSACTION.

Cancer Genetics Reports Q4 Loss Per Share $0.14

April 16 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.14.QTRLY REVENUE INCREASED SEQUENTIALLY BY 15%, FROM $5.9 MILLION IN Q3 TO $6.8 MILLION IN Q4.CONTINUES TO ENGAGE RAYMOND JAMES & ASSOCIATES, INC. AS A FINANCIAL ADVISOR TO ASSIST WITH EVALUATING OPTIONS.OPTIONS MAY INCLUDE RAISING ADDITIONAL CAPITAL, ACQUISITION OF ANOTHER COMPANY AND / OR COMPLEMENTARY ASSETS.OPTIONS MAY ALSO INCLUD SALE OF COMPANY, OR ANOTHER TYPE OF STRATEGIC PARTNERSHIP.

Cancer Genetics Announces Pricing Of $3.5 Million Public Offering Of Common Stock

Jan 28 (Reuters) - :CANCER GENETICS, INC. ANNOUNCES PRICING OF $3.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 15.2 MILLION COMMON SHARES PRICED AT $0.23 PER SHARE.

Cancer Genetics, Inc. Announces Proposed Public Offering Of Common Stock

Jan 28 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CANCER GENETICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO PAY ANY AMOUNTS REQUIRED TO PAY TO LENDERS, OTHERS.

Cancer Genetics & Certain Units Entered Forbearance & 5th Amendment To Amended & Restated Loan & Security Agreement

Jan 16 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS - CO, CERTAIN UNITS ENTERED FORBEARANCE & 5TH AMENDMENT TO AMENDED & RESTATED LOAN & SECURITY AGREEMENT.CANCER GENETICS INC - AMENDMENT EXTENDS REVOLVING LINE MATURITY DATE TO APRIL 15, 2019.CANCER GENETICS - CO, CERTAIN UNITS ALSO ENTERED INTO FORBEARANCE AGREEMENT & MODIFICATION NO. 4 TO LOAN & SECURITY AGREEMENT DATED MARCH 22, 2017.CANCER GENETICS - AMENDED LOAN AGREEMENT UNDER FORBEARANCE AGREEMENT & MODIFICATION NO. 4 IS INTEREST-ONLY $6 MILLION TERM LOAN, MATURES ON MARCH 22, 2020.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up